Guggenheim Capital LLC Recursion Pharmaceuticals, Inc. Transaction History
Guggenheim Capital LLC
- $12 Billion
- Q4 2024
A detailed history of Guggenheim Capital LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 143,057 shares of RXRX stock, worth $908,411. This represents 0.01% of its overall portfolio holdings.
Number of Shares
143,057
Previous 155,230
7.84%
Holding current value
$908,411
Previous $1.02 Million
5.38%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding RXRX
# of Institutions
341Shares Held
284MCall Options Held
2.83MPut Options Held
3.64M-
Vanguard Group Inc Valley Forge, PA34MShares$216 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.3MShares$205 Million1.91% of portfolio
-
Baillie Gifford & CO24.9MShares$158 Million0.13% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$110 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$93.1 Million0.44% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.15B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...